Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr45.50 SEK
Change Today -0.40 / -0.87%
Volume 82.5K
CEVI On Other Exchanges
As of 11:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

cellavision ab (CEVI) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/7/15 - kr56.00
52 Week Low
10/16/14 - kr24.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLAVISION AB (CEVI)

Related News

No related news articles were found.

cellavision ab (CEVI) Related Businessweek News

No Related Businessweek News Found

cellavision ab (CEVI) Details

CellaVision AB (publ) develops and sells systems for routine analysis of blood and other body fluids in health care services sector. The company offers analyzers, supplementary software, and peripheral equipment for digital microscopy in the sub-field of hematology. It provides CellaVision DM9600 and CellaVision DM1200, which automatically perform a preliminary differential count on peripheral blood or body fluid smears, as well as pre-classify the white blood cells, pre-characterize parts of the red morphology, and offer functionality for platelet estimation; DI-60, an automated blood analysis line; and CellaVision DM9600 Vet and CellaVision DM1200 Vet for blood analysis at veterinary laboratories. The company’s products comprise CellaVision Body Fluid Application for analyzing body fluids, including cerebrospinal, pleural and synovial fluids; CellaVision Remote Review Software Citrix Ready that enables remote users to access analyzed slides, and reclassify cells and sign slides from another location; CellaVision Proficiency Software, a Web-based program for testing of blood and body fluid differentials; CellaVision Image Capture System that allows small labs performing differentials to streamline patient care; CellaVision Peripheral Blood Application for white blood cell differential, red blood cell characterization, and platelet estimation; CellaVision Advanced RBC Application, which performs pre-characterization of red blood cells; and CellAtlas mobile app. It also offers CellaVision Light Tower that provides visual and audible signals of the status of a CellaVision DM Analyzer; HemaPrep, an automated blood smearing instrument for blood cell analysis; and barcode label printer kit for reading and copying barcodes and generating barcode labels. The company sells its products to hospital and commercial laboratories in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision AB (publ) was founded in 1994 and is headquartered in Lund, Sweden.

70 Employees
Last Reported Date: 07/17/15
Founded in 1994

cellavision ab (CEVI) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cellavision ab (CEVI) Key Developments

Cellavision AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year 2015

CellaVision AB reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, net sales decreased by 5.0% to SEK 51.5 million compared to SEK 54.2 million a year ago. The operating profit was SEK 8.3 million against SEK 10.8 million a year ago. The pre-tax profit was SEK 7.7 million against SEK 11.4 million a year ago. Earnings per share were SEK 0.21 against SEK 0.38 a year ago. Negative cash flow was SEK 26.7 million against SEK 30.0 million a year ago. For the six months, net sales increased by 6.0% to SEK 103.3 million against SEK 97.4 million a year ago. The operating profit increased to SEK 18.8 million against SEK 18.3 million a year ago. The pre-tax profit decreased to SEK 18.5 million against SEK 18.9 million a year ago. Earnings per share decreased to SEK 0.55 against SEK 0.63 a year ago. Cash flow was SEK 14.4 million against negative cash flow of SEK 11.7 million a year ago. Follow-up order in the veterinary market worth more than SEK 30 million and expected operating profit for the full year 2015 exceeding SEK 65 million (42.8). Revised operating margin target from 15% to 20% over an economic cycle.

CellaVision AB Provides Earnings Guidance for the Second Quarter of 2015

CellaVision AB provided earnings guidance for the second quarter of 2015. Company foresees that sales in the second quarter of 2015 will be somewhat lower than the strong comparative quarter of 2014. In view of the above CellaVision chooses to inform the market in this particular case that CellaVision's expected operating income, EBIT for the full year 2015, will exceed SEK 65 million. The company revised its financial target regarding the operating margin from 15% to 20% over an economic cycle. This is primarily done because of CellaVision scalable and cost-effective business model.

CellaVision Receives an Additional Order from a Veterinary Laboratory Chain in the US Market

CellaVision has received an additional order from a veterinary laboratory chain in the US market. The order includes equipment for the customer's laboratories and will be delivered before the end of the year. The order has a value of over SEK 30 million and is in addition to the order communicated in the last quarter of 2014 which included a delivery of instruments exceeding SEK 10 million. The market for company equipment in the veterinary sector is characterized by few but relatively large players. The company will continue to actively assess and opportunistically address the veterinary market segment. During the first quarter of 2015 company delivered and installed the instruments, CellaVision(R) DM9600 Vet and CellaVision(R) DM1200 Vet to the customer previously communicated in the fourth quarter of 2014. The company has continued to develop its unique veterinary software during the first six months of 2015 in order to meet the specialized needs of the large veterinary laboratory. An example of this is the ability to analyze dog and cat blood remotely and in real-time using CellaVision(R) Remote Review Software. This enables laboratory chains that work in networks to share test results and cell images efficiently. The company has had products addressing the veterinary laboratories since 2012. The primary target group is the approximately 100 larger veterinary laboratories in the US and Canada, where the volume of samples is high and the need for an effective analytical method is great. The products are an adapted version of CellaVision's existing instruments for human blood with the capacity to analyze blood from the most common pets, i.e., dog and cat. CellaVision(R) DM9600 Vet and CellaVision(R) DM1200 Vet replaces a manual microscope for blood analysis in the veterinary laboratories. Although the great potential is in North America, company sees future business opportunities in addressing customers in other regions. The company sells the product directly to end customers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CEVI:SS kr45.50 SEK -0.40

CEVI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $46.02 USD +0.38
Siemens AG €88.35 EUR -0.286
Sysmex Corp ¥7,250 JPY -200.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CEVI Industry Range
Price/Earnings 35.8x
Price/Sales 4.8x
Price/Book 7.4x
Price/Cash Flow 35.8x
TEV/Sales 4.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLAVISION AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at